Format

Send to

Choose Destination
See comment in PubMed Commons below
Gut Liver. 2014 Sep;8(5):526-35. doi: 10.5009/gnl13370. Epub 2014 Jul 25.

Effective biliary drainage and proper treatment improve outcomes of hepatocellular carcinoma with obstructive jaundice.

Author information

1
Departments of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea.
2
Departments of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Abstract

BACKGROUND/AIMS:

We investigated the treatment outcomes and prognostic factors of hepatocellular carcinoma (HCC) with obstructive jaundice.

METHODS:

Among 2,861 patients newly diagnosed with HCC between 2002 and 2011, a total of 63 patients who initially presented with obstructive jaundice were analyzed. Only four patients presented with resectable tumors and underwent curative resection. In the other patients who presented with unresectable tumors, 5, 8, 9, and 18 patients received transarterial chemoembolization (TACE), chemotherapy, radiotherapy, and combined treatment, respectively. Both the clinical and the treatment factors that affect overall survival (OS) were analyzed.

RESULTS:

The median OS was 4 months, and the 1-year OS rate was 23%. Patients who received treatment for HCC had a significantly improved OS rate compared with the patients who received supportive care only (1-year OS, 32% vs 0%; p<0.01). Responders to treatment showed a better OS than nonresponders (1-year OS, 52% vs 0%; p<0.01). TACE and radiotherapy resulted in relatively good treatment responses of 64% and 67%, respectively. In multivariate analyses, treatment of HCC (p=0.02) and the normalization of serum bilirubin by biliary drainage (p=0.02) were significantly favorable prognostic factors that affected the OS.

CONCLUSIONS:

Unresectable HCC with obstructive jaundice has a poor prognosis. However, effective biliary drainage and treatment of HCC such as with TACE or radiotherapy improves survival.

KEYWORDS:

Drug therapy; Radiotherapy; Transarterial chemoembolization

PMID:
25071072
PMCID:
PMC4164257
DOI:
10.5009/gnl13370
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Inforang Icon for PubMed Central
    Loading ...
    Support Center